Press Releases Repare Therapeutics Inc.

Equities

RPTX

US7602731025

Real-time Estimate Cboe BZX Other stock markets 12:31:33 30/04/2024 am IST			5-day change	1st Jan Change
3.175 ^USD	-0.78%		-2.76%	-56.58%

26/04	Repare Therapeutics Inc. Announces Directorate Changes	CI
28/02	Repare Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors	27/04	BU
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	21/03	BU
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	16/03	BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX	12/03	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX	03/03	PR
Repare Therapeutics to Participate in Two Upcoming Investor Conferences	29/02	BU
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	28/02	BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX	24/02	PR
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX)	17/02	BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX	16/02	PR
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664	15/02	BU
Repare Therapeutics to Regain Global Rights to Camonsertib	13/02	BU
Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment	25/01	BU
Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones	08/01	BU
Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer	05/01	BU
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans	30/12	BU
Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024, RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Pol Inhibitor	16/11	AQ
Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor	15/11	BU
Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results	09/11	BU
VedaBio Unveils World Class Scientific Advisory Board	08/11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Repare Therapeutics Inc.

Equities

RPTX

US7602731025

Press Releases

Filters